Assessing quality in decision analytic cost-effectiveness models: A suggested framework and example of application

PharmacoEconomics

Volumn 17, Issue 5, 2000, Pages 461-477

  Sculpher, Mark ^a   Fenwick, Elisabeth ^a   Claxton, Karl ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DECISION THEORY; HEALTH CARE COST; PRIORITY JOURNAL; QUALITY CONTROL; STATISTICAL MODEL;

EID: 0034101206     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017050-00005     Document Type: Conference Paper

References (44)

1. 1. Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993; 13: 322-38
2. 2. Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan F. editor. Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995: 185-205
3. 3. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness analysis in health and medicine. New York (NY): Oxford University Press, 1996
4. 4. Briggs A, Sculpher MJ. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409
5. 5. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1-11
6. 6. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-27
7. 7. Popper KR. The logic of scientific discovery. London: Hitchinson, 1972
8. 8. Lakatos I. Falsification and the methodology of scientific research programmes. In: Lakatos I, Musgrave, A, editors. Criticism and the growth of knowledge. Cambridge: Cambridge University Press, 1970: 91-195
9. 9. Manning R, Claxton K. Experimental and econometric solutions to selection bias. The International Health Economics Association Meeting, 1999 Jun 6-9; Rotterdam
10. 10. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis 1967; 20: 637-48
11. 11. Sonnenberg FA, Roberts MS, Tsevat J. Toward a peer review process for medical decision analysis models. Med Care 1994; 32Suppl.: JS52-64
12. 12. Russell B. My philosophical development. London: Routledge, 1959
13. 13. Sokal A, Bricmont J. Intellectual impostures. London: Profile Books, 1998
14. 14. Feyerabend P. Against method. London: New Left Books, 1975
15. 15. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. JAMA 1996; 276: 637-9
16. 16. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature: II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994; 271: 59-63
17. 17. Pocock SJ. When to stop a clinical trial. BMJ 1992; 305: 235-40
18. 18. Eddy DM. Technology assessment: the role of mathematical modeling. In: Mosteller F, editor. Assessing medical technologies. Washington, DC: National Academy Press, 1985: 144-53
19. 19. Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998; 1: 131-47
20. 20. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York (NY): Oxford University Press, 1997
21. 21. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-83
22. 22. Nuijten MJC, Starzewski J. Applications of modelling studies. Pharmacoeconomics 1998; 13: 289-91
23. 23. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38-42
24. 24. Palmer CS, Revicki DA, Genduso LA, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manag Care 1998; 4: 345-55
25. 25. Mohr P, Neumann P, Claxton K. Letter to the editor. Am J Manag Care 1998; 4: 1200-1
26. 26. Peralta V, Cuesta MJ, de Leon J. An empirical analysis of latent structures underlying schizophrenic symptoms: a four-syndrome model. Biol Psychiatry 1994; 36: 726-36
27. 27. Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522-3
28. 28. Patrick DL, Erickson P. Health status and health policy: allocating resources to health care. New York (NY): Oxford University Press, 1993
29. 29. Sugar CA, Sturm R, Lee TT, et al. Empirically defined health states for depression from the SF-12. Health Serv Res 1998; 33: 911-28
30. 30. Deyo RA, Centor RM. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 1986; 39: 897-906
31. 31. Van Doorslaer EKA. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis. Dermatology 1996; 193: 239-44
32. 32. Sculpher M, Michaels J, McKenna M, et al. A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12: 104-25
33. 33. Daly E, Vessey MP, Barlow D, et al. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996; 23: 247-57
34. 34. Coulter A, Bradlow J, Agass M, et al. Outcomes of referrals to gynaecology outpatient clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol 1991; 98: 789-96
35. 35. Luoto R, Kaprio J, Uutela A. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994; 139: 64-76
36. 36. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52-8
37. 37. Dowie J. Evidence-based, cost-effective and preference-driven medicine: decision analysis based medical decision making is the pre-requisite. J Health Serv Res Policy 1996; 1: 104-13
38. 38. Fenwick E, Claxton K, Sculpher M, et al. Improving the efficiency and relevance of health technology assessment: the role of iterative decision analytic modelling. Centre for Health Economics (CHE) discussion paper. York: CHE, University of York. In press
39. 39. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95-104
40. 40. Thompson KM, Graham JD. Going beyond the single number: using probabilistic risk assessment to improve risk management. Hum Ecological Risk Assess 1996; 24: 1008-34
41. 41. Thompson KM, Burmaster DE, Crouch EAC. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments. Risk Anal 1992; 12: 53-63
42. 42. Stinnett A, Paltiel D. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of the means. Med Decis Making 1997; 17: 483-9
43. 43. Tosteson ANA, Rosenthal DI, Melton J, et al. Cost-effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594-603
44. 44. Briggs A, Sculpher M, Britton A, et al. The costs and benefits of primary total hip replacement: how likely are new prostheses to be cost-effective? Int J Technol Assess Health Care 1998; 14 (4): 743-61